Search

Your search keyword '"Scott, David W."' showing total 20 results
Start Over Author "Scott, David W." Journal british journal of haematology
20 results on '"Scott, David W."'

1. ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells

Author

Chung, Elaine Y. L., primary, Sartori, Giulio, additional, Ponzoni, Maurilio, additional, Cascione, Luciano, additional, Priebe, Valdemar, additional, Xu‐Monette, Zijun Y., additional, Fang, Xiaosheng, additional, Zhang, Mingzhi, additional, Visco, Carlo, additional, Tzankov, Alexandar, additional, Rinaldi, Andrea, additional, Sgrignani, Jacopo, additional, Zucca, Emanuele, additional, Rossi, Davide, additional, Cavalli, Andrea, additional, Inghirami, Giorgio, additional, Scott, David W., additional, Young, Ken H., additional, and Bertoni, Francesco, additional

Published
2023
Full Text
View/download PDF

5. Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia

Author

Zhu, Kai, primary, Jamroz, Andrew, additional, Huang, Steven, additional, Villa, Diego, additional, Freeman, Ciara L., additional, Scott, David W., additional, Slack, Graham, additional, Sehn, Laurie H., additional, Connors, Joseph M., additional, Toze, Cynthia L., additional, Savage, Kerry J., additional, and Gerrie, Alina S., additional

Published
2022
Full Text
View/download PDF

7. The impact of surveillance imaging after curative‐intent radiotherapy for limited‐stage follicular lymphoma

Author

Urban, Ryan, primary, Chow, Ryan, additional, Pickles, Tom, additional, Chan, Matthew, additional, Livergant, Jonathan, additional, Gerrie, Alina S., additional, Freeman, Ciara, additional, Sehn, Laurie, additional, Scott, David W., additional, Villa, Diego, additional, Farinha, Pedro, additional, Gondara, Lovedeep, additional, Savage, Kerry J., additional, and Lo, Andrea C., additional

Published
2021
Full Text
View/download PDF

9. Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma

Author

Calvente, Lourdes, primary, Tremblay‐LeMay, Rosemarie, additional, Xu, Wei, additional, Chan, Fong Chun, additional, Hong, Michael, additional, Zhang, Tong, additional, Yhim, Ho‐Young, additional, Kuruvilla, John, additional, Crump, Michael, additional, Kukreti, Vishal, additional, Prica, Anca, additional, Regier, Dean, additional, Marra, Marco A., additional, Karsan, Aly, additional, Steidl, Christian, additional, Scott, David W., additional, Sabatini, Peter, additional, and Kridel, Robert, additional

Published
2020
Full Text
View/download PDF

11. Identification of high‐riskDUSP 22‐rearranged ALK ‐negative anaplastic large cell lymphoma

Author

Hapgood, Greg, primary, Ben‐Neriah, Susana, additional, Mottok, Anja, additional, Lee, Derrick G., additional, Robert, Kridel, additional, Villa, Diego, additional, Sehn, Laurie H., additional, Connors, Joseph M., additional, Gascoyne, Randy D., additional, Feldman, Andrew L., additional, Farinha, Pedro, additional, Steidl, Christian, additional, Scott, David W., additional, Slack, Graham W., additional, and Savage, Kerry J., additional

Published
2019
Full Text
View/download PDF

12. Validation of a simplified international prognostic score (IPS‐3) in patients with advanced‐stage classic Hodgkin lymphoma.

Author

Hayden, Anna R., Lee, Derrick G., Villa, Diego, Gerrie, Alina S., Scott, David W., Slack, Graham W., Sehn, Laurie H., Connors, Joseph M., and Savage, Kerry J.

Subjects
HODGKIN'S disease, BLEOMYCIN, TALLIES
Abstract

Summary: A novel prognostic score (IPS‐3), comprised of only three of the seven IPS‐7 indicators (age ≥45, stage IV, haemoglobin <105 g/l), was recently proposed as a simplified model for advanced‐stage classic Hodgkin lymphoma (cHL). We aimed to validate this model in advanced‐stage cHL patients treated with doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) in British Columbia. The estimated five‐year freedom from progression (FFP) for scores of 0, 1, 2 and 3 were very similar to the original report at 84%, 76%, 72% and 68% respectively. The IPS‐3 score is highly reproducible in this independent dataset and its simplicity makes it appealing for everyday clinical practice. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

13. Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network

Author

Rauert‐Wunderlich, Hilka, primary, Mottok, Anja, additional, Scott, David W., additional, Rimsza, Lisa M., additional, Ott, German, additional, Klapper, Wolfram, additional, Unterhalt, Michael, additional, Kluin‐Nelemans, Hanneke C., additional, Hermine, Olivier, additional, Hartmann, Sylvia, additional, Thorns, Christoph, additional, Rymkiewicz, Grzegorz, additional, Holte, Harald, additional, Dreyling, Martin, additional, Hoster, Eva, additional, and Rosenwald, Andreas, additional

Published
2018
Full Text
View/download PDF

14. The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy

Author

Holte, Harald, primary, Beiske, Klaus, additional, Boyle, Merrill, additional, Trøen, Gunhild, additional, Blaker, Yngvild N., additional, Myklebust, June, additional, Kvaløy, Sunniva, additional, Rosenwald, Andreas, additional, Lingjaerde, Ole C., additional, Rimsza, Lisa M., additional, Smeland, Erlend B., additional, Scott, David W., additional, and Kolstad, Arne, additional

Published
2018
Full Text
View/download PDF

15. Identification of high‐risk DUSP22‐rearranged ALK‐negative anaplastic large cell lymphoma.

Author

Hapgood, Greg, Ben‐Neriah, Susana, Mottok, Anja, Lee, Derrick G., Robert, Kridel, Villa, Diego, Sehn, Laurie H., Connors, Joseph M., Gascoyne, Randy D., Feldman, Andrew L., Farinha, Pedro, Steidl, Christian, Scott, David W., Slack, Graham W., and Savage, Kerry J.

Subjects
BACTERIAL artificial chromosomes, ANAPLASTIC lymphoma kinase, PROGRESSION-free survival
Published
2019
Full Text
View/download PDF

16. Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience

Author

Hapgood, Greg, primary, Pickles, Tom, additional, Sehn, Laurie H., additional, Villa, Diego, additional, Klasa, Richard, additional, Scott, David W., additional, Gerrie, Alina S., additional, Gascoyne, Randy D., additional, Slack, Graham W., additional, Parsons, Christina, additional, Morris, James W., additional, Connors, Joseph M., additional, and Savage, Kerry J., additional

Published
2016
Full Text
View/download PDF

17. Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model

Author

Kansara, Roopesh, primary, Villa, Diego, additional, Gerrie, Alina S., additional, Klasa, Richard, additional, Shenkier, Tamara, additional, Scott, David W., additional, Slack, Graham W., additional, Gascoyne, Randy D., additional, Connors, Joseph M., additional, Sehn, Laurie H., additional, and Savage, Kerry J., additional

Published
2016
Full Text
View/download PDF

18. Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.

Author

Rauert‐Wunderlich, Hilka, Mottok, Anja, Scott, David W., Rimsza, Lisa M., Ott, German, Klapper, Wolfram, Unterhalt, Michael, Kluin‐Nelemans, Hanneke C., Hermine, Olivier, Hartmann, Sylvia, Thorns, Christoph, Rymkiewicz, Grzegorz, Holte, Harald, Dreyling, Martin, Hoster, Eva, and Rosenwald, Andreas

Subjects
MANTLE cell lymphoma, GENE expression, INCURABLE diseases, PROGNOSIS
Abstract

Summary: Mantle cell lymphoma (MCL) is still considered incurable and the course of the disease is highly variable. Established risk factors include the Mantle Cell Lymphoma International Prognostic Index (MIPI) and the quantification of the proliferation rate of the tumour cells, e.g. by Ki‐67 immunohistochemistry. In this study, we aimed to validate the prognostic value of the gene expression‐based MCL35 proliferation assay in patient cohorts from randomized trials of the European Mantle Cell Lymphoma Network. Using this assay, we analysed the gene expression proliferation signature in routine diagnostic lymph node specimens from MCL Younger and MCL Elderly trial patients, and the calculated MCL35 score was used to assign MCL patients to low (61%), standard (27%) or high (12%) risk groups with significantly different outcomes. We confirm here in our prospective clinical trial cohort of MCL patients, that the MCL35 assay is strongly prognostic, providing additional information to the Ki‐67 index and the MIPI. Thus, this robust assay may assist in making treatment decisions or in devising risk‐adapted prospective clinical trials in the future. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

20. A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma.

Author

Kuruvilla J, Rushton C, Villa D, Aslam M, Prica A, Abdel Samad N, Doucet S, Dudebout J, Fleury I, Fraser G, Larouche JF, Shafey M, Skrabek P, Skamene T, Morin RD, Alcaide M, Ben-Neriah S, Lee D, Winch C, Shepherd LE, Scott DW, Crump M, Chen BE, and Hay AE

Subjects
Humans, Female, Male, Middle Aged, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Recurrence, Pyrimidines therapeutic use, Pyrimidines administration & dosage, Pyrazoles therapeutic use, Pyrazoles administration & dosage, Hematopoietic Stem Cell Transplantation, Adenine analogs & derivatives, Adenine therapeutic use, Lymphoma, Large B-Cell, Diffuse drug therapy, Piperidines therapeutic use
Abstract

In the LY.17 randomized phase II clinical trial, adults with relapsed and refractory diffuse large B-cell lymphoma treated with ibrutinib-R-GDP (IR-GDP) for up to three cycles had more documented bacterial and fungal infections, without improvement in overall response, compared with R-GDP. CR, complete response; DLBCL, diffuse large B-cell lymphoma; PD, progressive disease; PR, partial response; R/R, relapsed/refractory; SD, stable disease., (© 2024 British Society for Haematology and John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results